Hippocratic AI vs Tempus

Tempus has a disclosed valuation of $8.1B, while Hippocratic AI's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Hippocratic AI's $120M — a gap of $930M. Combined, the two companies have completed 7 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Hippocratic AI sits at 65/100. That 19-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Hippocratic AI was founded by Munjal Shah in 2023. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Hippocratic AI: Hippocratic AI develops a safety-focused AI platform designed to address the global shortage of healthcare professionals by deploying AI agents that perform patient-facing healthcare communication tasks including care navigation, medication adherence outreach, chronic disease monitoring, and post-discharge follow-up. The platform is built around a healthcare-specific large language model with extensive safety evaluation against clinical benchmarks.\n\nThe company raised approximately 120 million USD in early rounds and has established partnerships with health systems and payers focused on reducing care gaps and improving patient engagement at scale. Hippocratic positions its AI as augmenting the healthcare workforce rather than replacing clinicians, targeting the vast volume of lower-acuity patient interactions that do not require physician judgment.\n\nThe healthcare staffing shortage is a structural problem projected to worsen over the next decade, creating durable demand for AI solutions that extend the capacity of existing clinical teams. Hippocratic AI competes with ambient clinical AI companies and general-purpose AI assistant platforms, but its narrow vertical focus on patient-facing healthcare communication and its safety-first design philosophy position it to navigate the regulatory and liability landscape that general AI platforms are less equipped to manage. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Tempus got there first, launching in 2015 — that's 8 years of extra runway. Hippocratic AI didn't arrive until 2023. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Hippocratic AI has about 50-200 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Hippocratic AI and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.